{"pub": "washingtontimes", "url": "https://washingtontimes.com/news/2019/oct/22/company-says-it-will-seek-approval-of-alzheimers-d", "downloaded_at": "2019-10-22 14:02:55.296280+00:00", "title": "Company says it will seek approval of Alzheimer's drug", "language": "en", "text": "The drug company Biogen Inc. says it will seek federal approval for a medicine to treat early Alzheimer\u2019s disease, a landmark step toward finding a treatment that can alter the course of the most common form of dementia.\n\nThe announcement Tuesday is a surprise because the company earlier this year stopped two studies of the drug when partial results suggested it was not working. The company now says a new analysis of more results suggest that the drug helped reduce a decline of thinking skills at the highest dose.\n\nThe drug, called aducanumab, aims to help the body clear harmful plaques from the brain. Cambridge, Massachusetts-based Biogen is developing it with a Japanese company, Eisai Co. Ltd.\n\nShares of Biogen soared 36% to $305 in pre-market trading Tuesday.\n\nSign up for Daily Newsletters Manage Newsletters\n\nCopyright \u00a9 2019 The Washington Times, LLC.", "description": "The drug company Biogen Inc. says it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of the most common form of dementia.", "authors": ["The Washington Times Http", "Marilynn Marchione"], "top_image": "", "published_at": "2019-10-22"}